This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2014 Feb;11(2):63.

doi: 10.1038/nrcardio.2013.201. Epub 2013 Dec 10.

Dyslipidaemia: 1-Year results from OSLER trial of anti-PCSK9 monoclonal antibody evolocumab

Bryony M Mearns

PMID: 24322554
DOI: 10.1038/nrcardio.2013.201

Comment

Dyslipidaemia: 1-Year results from OSLER trial of anti-PCSK9 monoclonal antibody evolocumab

Bryony M Mearns. Nat Rev Cardiol. 2014 Feb.

. 2014 Feb;11(2):63.

doi: 10.1038/nrcardio.2013.201. Epub 2013 Dec 10.

Author

Bryony M Mearns

PMID: 24322554
DOI: 10.1038/nrcardio.2013.201

No abstract available

PubMed Disclaimer

Comment on

Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial.
Koren MJ, Giugliano RP, Raal FJ, Sullivan D, Bolognese M, Langslet G, Civeira F, Somaratne R, Nelson P, Liu T, Scott R, Wasserman SM, Sabatine MS; OSLER Investigators. Koren MJ, et al. Circulation. 2014 Jan 14;129(2):234-43. doi: 10.1161/CIRCULATIONAHA.113.007012. Epub 2013 Nov 19. Circulation. 2014. PMID: 24255061 Clinical Trial.

References

1. Circulation. 2014 Jan 14;129(2):234-43 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal